针对 SARS-CoV-2 的预先存在的体液交叉反应性免疫的证据和影响。
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
机构信息
Unité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU-Mère-Enfant, Fondation Jeanne EBORI, Libreville, Gabon.
Center de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
出版信息
Immun Inflamm Dis. 2021 Mar;9(1):128-133. doi: 10.1002/iid3.367. Epub 2020 Dec 15.
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic.
AIM
We aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2.
METHOD
We have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay.
RESULTS
Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies.
CONCLUSION
Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
背景
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）已在全球范围内出现。围绕新冠病毒建立知识对于制定基于事实的方法来有效应对这一大流行病至关重要。
目的
我们旨在研究针对 SARS-CoV-2 的预先存在的体液交叉反应性免疫。
方法
我们已经测试了来自 2014 年健康医护志愿者的血清对 SARS-CoV-2 核衣壳（N）抗原的反应性。我们使用经过充分验证的血清学平台（Elecsys 测定法）评估了针对 SARS-CoV-2 N 抗原的免疫球蛋白反应性。
结果
32 份血清（135 份中的 32 份[23.7%]）对 SARS-CoV-2 N 抗原呈反应性，表明存在针对 SARS-CoV-2 N 抗原的抗体。
结论
尽管观察到的反应性的临床相关性只能推测，需要进一步研究，但这一发现对 2019 年冠状病毒病血清流行病学调查和疫苗临床试验具有重要意义。
Zotero 插件